COR-005 (veldoreotide) is an investigational somatostatin analogue (SSA) in development for treatment of patients with acromegaly. SSAs bind to somatostatin receptors, inhibiting secretion of growth hormone. It is beleived that COR-005 may offer an improved safety and efficacy profile—compared with current SSAs—because of its differentiated activation of somatostatin receptor subtypes. COR-005 has received orphan drug designation for acromegaly in the US and EU. COR-005 (veldoreotide) is currently being optimized for sustained release and subcutaneous delivery.
|Lab Codes||COR-005, DG-3173, PTR-3173|
|Chemical Name||Glycinamide, N-(4-amino-1-oxobutyl)-L-phenylalanyl-L-tryptophyl-D-tryptophyl-L-lysyl-L-threonyl-L-phenylalanyl-N2-(3-carboxypropyl)-, (7→1)-lactam|
|Cas Registry Number||252845-37-7|
|Orphan Drug Status||Yes|
|New Molecular Entity||Yes|
|Developer||Cortendo AB, Strongbridge Biopharma plc, Aspireo Pharmaceuticals Limited|
|Mechanism Of Action||Somatostatin receptor 2, 4 and 5 agonist.|